For research use only. Not for therapeutic Use.
Ropivacaine-d7 (CAS: 684647-62-9), a premium pharmaceutical research compound designed for advanced anesthetic and pain management studies. As a deuterated analog of Ropivacaine, it offers enhanced stability and improved pharmacokinetic properties. Ropivacaine-d7 is ideal for use in pharmacological and biochemical research, providing precise and reliable data for your studies. This high-purity compound ensures consistent results, aiding in the development of novel anesthetic and pain relief therapies. Trusted by leading laboratories, Ropivacaine-d7 is your go-to solution for cutting-edge anesthetic research. Unlock new possibilities in pain management and anesthesia with Ropivacaine-d7, where innovation meets reliability.
Catalog Number | S000235 |
CAS Number | 684647-62-9 |
Molecular Formula | C17H19D7N2O |
Purity | ≥95% |
IUPAC Name | (2S)-N-(2,6-dimethylphenyl)-1-(1,1,2,2,3,3,3-heptadeuteriopropyl)piperidine-2-carboxamide |
InChI | InChI=1S/C17H26N2O/c1-4-11-19-12-6-5-10-15(19)17(20)18-16-13(2)8-7-9-14(16)3/h7-9,15H,4-6,10-12H2,1-3H3,(H,18,20)/t15-/m0/s1/i1D3,4D2,11D2 |
InChIKey | ZKMNUMMKYBVTFN-YMXBPWPKSA-N |
SMILES | [2H]C([2H])([2H])C([2H])([2H])C([2H])([2H])N1CCCC[C@H]1C(=O)NC2=C(C=CC=C2C)C |
Reference | [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Dene Simpson, et al. Ropivacaine: a review of its use in regional anaesthesia and acute pain management. Drugs. 2005;65(18):2675-717. [3]. Li TF, et al. Epidural sustained release ropivacaine prolongs anti-allodynia and anti-hyperalgesia in developing and established neuropathic pain. PLoS One. 2015 Jan 24;10(1):e0117321. [4]. Hye Won Shin, et al. The inhibitory effects of bupivacaine, levobupivacaine, and ropivacaine on K2P (two-pore domain potassium) channel TREK-1. J Anesth [5]. Milan Patel, et al. Ropivacaine Inhibits Pressure-Induced Lung Endothelial Hyperpermeability in Models of Acute Hypertension. Life Sci. 2019 Apr 1;222:22-28. |